Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Flow cytometry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB1561 - Provider product page
- Provider
- R&D Systems
- Product name
- Human PD-L1 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human PD-L1/B7-H1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) B7-1, -2, -H2, -H3, -H3b, -H4, rhPD-L2, recombinant mouse B7-H1, recombinant rat (rr) B7-1, or rrB7-2 is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
Q9NZQ7- Isotype
- IgG
- Antibody clone number
- 130021
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy.
Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
Frequent expression of PD-L1 on circulating breast cancer cells.
Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.
IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation.
Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, Murrone A, Bianchi F, Amantini C, Giulietti M, Ricci G, Principato G, Santoni G, Berardi R, Cascinu S
PloS one 2019;14(5):e0215990
PloS one 2019;14(5):e0215990
Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.
Cristiani CM, Turdo A, Ventura V, Apuzzo T, Capone M, Madonna G, Mallardo D, Garofalo C, Giovannone ED, Grimaldi AM, Tallerico R, Marcenaro E, Pesce S, Del Zotto G, Agosti V, Costanzo FS, Gulletta E, Rizzo A, Moretta A, Karre K, Ascierto PA, Todaro M, Carbone E
Cancer immunology research 2019 May;7(5):841-852
Cancer immunology research 2019 May;7(5):841-852
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.
Kammerer-Jacquet SF, Brunot A, Bensalah K, Campillo-Gimenez B, Lefort M, Bayat S, Ravaud A, Dupuis F, Yacoub M, Verhoest G, Peyronnet B, Mathieu R, Lespagnol A, Mosser J, Edeline J, Laguerre B, Bernhard JC, Rioux-Leclercq N
Urologic oncology 2017 Oct;35(10):603.e7-603.e14
Urologic oncology 2017 Oct;35(10):603.e7-603.e14
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS
Cancer immunology research 2017 Jun;5(6):480-492
Cancer immunology research 2017 Jun;5(6):480-492
Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
Kammerer-Jacquet SF, Crouzet L, Brunot A, Dagher J, Pladys A, Edeline J, Laguerre B, Peyronnet B, Mathieu R, Verhoest G, Patard JJ, Lespagnol A, Mosser J, Denis M, Messai Y, Gad-Lapiteau S, Chouaib S, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N
International journal of cancer 2017 Jan 1;140(1):142-148
International journal of cancer 2017 Jan 1;140(1):142-148
Frequent expression of PD-L1 on circulating breast cancer cells.
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C
Molecular oncology 2015 Nov;9(9):1773-82
Molecular oncology 2015 Nov;9(9):1773-82
Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.
Song X, Liu J, Lu Y, Jin H, Huang D
Oncology reports 2014 Mar;31(3):1191-8
Oncology reports 2014 Mar;31(3):1191-8
IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation.
Rojas D, Krishnan R
Immunology letters 2010 Aug 16;132(1-2):31-7
Immunology letters 2010 Aug 16;132(1-2):31-7
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- PD-L1/B7-H1 in Human Colon Cancer. PD-L1/B7-H1 was detected in formalin fixed paraffin-embedded sections of human colon cancer using Mouse Anti-Human PD-L1/B7-H1 Monoclonal Antibody (Catalog # MAB1561) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was observed in the cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of PD-L1/B7-H1 in Jurkat Human Cell Line by Flow Cytometry. Jurkat human acute T cell leukemia cell line was stained with Mouse Anti-Human PD-L1/B7-H1 Monoclonal Antibody (Catalog # MAB1561, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (Catalog # F0102B).View our protocol for Staining Membrane-associated Proteins.
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of PD-L1/B7-H1 in MDA-MB-231 Human Cell Line by Flow Cytometry. MDA-MB-231 human breast adenocarcinoma cell line was stained with Mouse Anti-Human PD-L1/B7-H1 Monoclonal Antibody (Catalog # MAB1561, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (Catalog # F0102B). Adherent cells were prepared by either manual scraping or with TrypLE Express treatment with similar results. View our protocol for Staining Membrane-associated Proteins.
